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ABSTRACT 
Background 
Hyperthyroidism is a common disease throughout the world, affecting 0.5%-2% of women 
and one-tenth as many men at some time. Graves’ disease and toxic nodular goitre are the 
two most common etiologies. Cardiovascular symptoms are often prominent, and atrial 
fibrillation (AF) is a well-known complication.  
Several large register studies have indicated that patients treated for hyperthyroidism may be 
at increased risk of death compared to the general population; it appears that this difference in 
mortality is chiefly attributable to cardiovascular and endocrine diseases. However, these 
previous studies are quite heterogenous with sometimes contradictory results. 
Subclinical hyperthyroidism (SH) is a condition afflicting approximately 1% of the 
population, defined as serum levels of thyroid-stimulating hormone (TSH) below the normal 
range while levels of triiodothyroxine (T3) and thyroxine (T4) are within the reference range. 
Symptoms are similar to, but milder than those seen in regular hyperthyroidism. AF, in 
particular, appears to occur more often when SH is present. 
 
Aims 
The aim of this thesis is to further investigate the correlation between hyperthyroidism and 
cardiovascular disease. Using a very large cohort based on register data, long-term 
cardiovascular mortality and morbidity (Paper I) were assessed in patients treated for 
hyperthyroidism. Another study addressed differences in long-term effects between 
treatments for hyperthyroidism (Paper II). In the last article, we attempted to find out whether 
subclinical hyperthyroidism might be a common cause of AF (Paper III). 
 
Methods 
Papers I-II were both based on essentially the same data on individuals with thyroid disease: 
Information on patients who had undergone thyroidectomy (complete or partial removal of 
the thyroid gland) was gathered from the Swedish National Patient Register, and information 
on patients treated with radioactive iodine was based on a material consisting of local hospital 
records. Data on cardiovascular outcomes and death was collected from the Patient Register, 
the Causes of Death Register, and Statistics Sweden. The Swedish Prescription Register was 
also used for assessment of levothyroxine treatment. Study subjects had undergone either 
surgery or radioiodine treatment between the years 1976-2000, and the cohort was followed 
until 2012.  
In Paper I, patients treated for nontoxic nodular goitre were used as a control group, but 
comparisons were also made to the general population of Stockholm. Outcomes were 
assessed in terms of all-cause mortality, cardiovascular mortality, and cardiovascular 
morbidity.  
In Paper II, which included only patients with hyperthyroidism, thyroidectomy was compared 
to radioiodine treatment in terms of all-cause and cause-specific mortality. Three different 
statistical methods were applied: Cox regression, propensity score matching, and inverse 
probability matching. 
Paper III was a cross-sectional observational study in which thyroid status was assessed 
among patients who underwent electrophysiological ablation for cardiac arrhythmias. Cases 
of AF were compared to controls with AV-nodal re-entry tachycardia with regard to thyroid 
hormone levels. The hypothesis was that AF would correlate to a higher prevalence of 
subclinical hyperthyroidism, defined as a suppression of TSH levels and normal free T4 
levels, compared to controls. 
 
Results 
In Paper I, an increased risk of all-cause mortality (hazard ratio (HR) 1.27 with a 95% 
confidence interval (CI) of 1.20-1.35) was found among the 12,239 patients treated for either 
Graves’ disease or toxic nodular goitre, compared to the 3,685 patients treated for nontoxic 
goitre. Increased cardiovascular mortality (HR 1.29, CI 1.17-1.42) and cardiovascular 
morbidity (HR 1.12, CI 1.06-1.18) was also seen, with AF being by far the most common 
finding at early follow-up. Furthermore, all of these outcomes were significantly more 
common in comparisons with the general population. The risk of death and cardiovascular 
disease was most evident in patients treated for toxic nodular goitre while only a weak 
association was seen among Graves’ disease patients. No decrease in risk was found among 
subjects included later (after 1990) compared to those included earlier. 
Paper II included 10,992 subjects with hyperthyroidism; 10,250 had been treated with 
radioiodine and 742 with thyroidectomy. Surgically treated subjects had lower all-cause 
mortality as assessed by cox regression (HR 0.82, CI 0.71-0.96), propensity score matching 
(HR 0.80, CI 0.68-0.94), and inverse probability weighting (0.85, CI 0.72-1.00, p = 0.044) 
compared to subjects who received radioiodine. Significantly lower cardiovascular mortality 
was also found among thyroidectomised individuals in all three analyses while no clear 
differences were found regarding cancer mortality or other causes of death. 
In Paper III, 312 patients were included. Of these, 212 had AF, and 100 had AV-nodal re-
entry tachycardia. Analyses showed that subclinical hyperthyroidism was not more common 
among subjects with AF than among control subjects. However, it was found that levels of 
free T4 were significantly higher in the AF group (CI of difference 0.03-1-35, p = 0.039). 
 
Conclusions 
Hyperthyroidism is associated with an increased risk of cardiovascular disease and death. The 
mechanisms behind this observation remain unknown, but some factors – notably 
hyperthyroidism due to toxic nodular goitre and treatment with radioiodine – seem to 
represent a stronger association. As for the specific diagnosis of AF, we found no clear 
evidence to support that subclinical hyperthyroidism might be one of the predominant 
underlying causes, although we did make the interesting observation that levels of free T4 
were significantly elevated among AF patients. 
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1 INTRODUCTION 
 
1.1 A TALE OF TWO DISEASES 
1.1.1 The history of cardiovascular disorders 
Diseases arising from the heart and vessels have most likely afflicted humankind since 
prehistoric times. Coronary calcification, the substrate for angina pectoris and myocardial 
infarction, has been demonstrated in mummies from ancient Egypt1. There are, however, no 
known historical records to prove that these conditions were acknowledged by the physicians 
of that era. It was not until 1772 that William Heberden, a British medical doctor, first gave 
an account of the symptoms typical for ischemic heart disease2. By contrast the clinical signs 
of cerebrovascular disease may have been noted as early as the 4th century B.C. by 
Hippocrates, the father of medicine, who coined the term “apoplexy” to signify a sudden loss 
of both speech and motor function. The expression means “struck down by force” – an 
analogy that still remains with us today as the word “stroke”3. As for cardiac arrhythmias, the 
measurement of a patient’s pulse is arguably one of the oldest known diagnostic tools. The 
ancient Greeks appear to have been almost obsessed by sphygmology (as the discipline was 
called), as were the Romans, Chinese and Indians; Ayurvedic teachings, for instance, mention 
some 600 different types of pulse4. The association between a slow pulse and fainting – both 
cardinal symptoms of atrioventricular block – was later described by Giovanni Batista 
Morgagni (in 1761), Robert Adams (1827), and William Stokes (1846), although only Adams 
and Stokes are credited with naming the syndrome2.  
The most common form of non-physiological tachycardia was probably described as early as 
1628 by William Harvey who documented “auricular fibrillation” in animals. The term was 
adequate and has not changed much since; it is known today as atrial fibrillation5. To be fair, 
it is possible that Harvey’s Chinese or Greek colleagues beat him to the post by a couple of 
millennia, at least in terms of describing atrial fibrillation symptoms; we will never know for 
certain. There is, however, little doubt that the first electrocardiographic recording of atrial 
fibrillation was made in 1909 by Sir Thomas Lewis, a British physician, who also noted that 
this arrhythmia was frequently found in patients with mitral stenosis6. 
 
1.1.2 The history of thyroid disorders 
An enlarged thyroid gland is called a goitre. If allowed to progress without treatment it 
becomes visible as a conspicuous swelling on the front of the neck. This probably contributed 
to goitres being mentioned in the oldest known medical text, “Emperor Shen Nung’s 
prescriptions”, written in China around 2700 B.C. Astoundingly, the author declared seaweed 
to be the cure. This was actually correct; seaweeds are rich in iodine, and iodine deficiency is 
a very common cause of goitre7. The same remedy was later suggested in records from other 
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cultures of the ancient world. In the 10th century A.D., Abul Kasim, renowned personal 
physician of the Andalusian caliph, removed the thyroid gland of a living subject - the first 
known account of such a procedure8. It took the medical community centuries to come up 
with an alternative cure for hyperthyroidism. In 1905 the American surgeon Robert Abbé 
treated Graves’ disease by implanting radium into a patient’s goitre9. This paved the way for 
radioiodine treatment which followed a few decades later, in the mid-1940s. 
 
1.1.3 The connection 
Caleb Hillier Parry (1755-1822) was a distinguished British physician and keen observer 
whose early reports of a number of medical conditions spanned several medical disciplines10. 
Not only did he describe angina pectoris and mitral stenosis, but he also gave a vivid account 
of “exophthalmic goitre” decades before his eponymic colleagues Robert Graves and Karl 
Adolph von Basedow defined the disease in 1834 and 1840, respectively. Parry wrote of a 
37-year-old woman with goitre whose eyes “protruded from their sockets… each systole of 
the heart shook the whole trunk of the body.” Although his notes were made in 1786, they 
were published posthumously. The first account of an association between the thyroid gland 
and the heart must therefore be credited to Guiseppe Flajani, physician to the Pope, who in 
1802 wrote about two patients with large thyroid glands, bulging eyes, and palpitations. The 
Italian, however, did not delve further into his discovery. He left it to Parry , Graves and von 
Basedow to ponder the strange triad of symptoms. They concluded that the aetiology was 
probably to be found in the heart and that the other 
findings were secondary manifestations. It took until the 
end of the 19th century for the medical community to 
realise that the thyroid gland was the site of the 
disease11. The first reports on the connection between 
thyrotoxicosis and specific cardiovascular diagnoses – 
in this case atrial fibrillation and heart failure, often in 
combination – were presented around 192012. At almost 
the same time, it was recognized that thyroidectomy 
could improve symptoms13. Some doctors named these 
patients “thyrocardiacs”; the most prominent 
thyrocardiac to this date might be former U.S. President 
George Bush Sr., who developed atrial fibrillation as a 
consequence of Graves’ disease.  
 
Figure 1. George Bush, U.S. president 
from 1989 to 1993, was diagnosed with 
atrial fibrillation deemed to be caused by 
Graves’ disease in 1991. 
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1.2 CARDIOVASCULAR DISEASE 
1.2.1 Overview 
Cardiovascular disease is one of the leading causes of disability and death in the Western 
world, accounting for between 30-45% of all mortality14,15. Within the cardiovascular 
spectrum, diagnoses such as myocardial infarction, stroke, and heart failure are the main 
culprits. However, recent decades have seen a dramatic reduction in cardiovascular deaths. 
To some extent this is due to improved treatment methods. To give a few examples, the first 
studies on the effect of reperfusion therapy to treat acute myocardial infarction were 
published in the early 1980s16. As for heart failure, the modern era of treatment has been said 
to have originated around 1990 when ACE-inhibitors and beta blockers were seen to reduce 
both mortality and morbidity17. Although these breakthroughs have profoundly affected the 
prognosis for many patients, efforts to prevent the occurrence of disease in the first place 
have also played – and continue to play – a very important role. To this end, the notion of 
primary prevention has been developed. It is based on two concepts: 1) to discover factors 
that are associated with future development of cardiovascular disease on the general 
population level, and 2) to find and, when possible, modify these risk factors in the individual 
patient. Primary prevention does not always have to take place in a healthcare setting. Public 
policy measures to reduce smoking, for example, have very likely had large effects on the 
incidence of coronary heart disease. Within the sphere of medicine, the recognition that 
hypertension causes harm to the heart and vessels has led to the development of a number of 
blood pressure lowering medications, which in turn has led to significant reductions in both 
mortality and morbidity18. The role of oral anticoagulants to prevent stroke in AF patients, or 
the importance of cholesterol lowering drugs in coronary heart disease, are two further 
discoveries from the last decades that deserve mentioning19. However, it is possible that not 
all risk factors in the cardiovascular field are yet known.  
 
1.2.2 Atrial fibrillation 
The most common cardiac arrhythmia is atrial fibrillation, a condition associated with 
symptoms such as palpitations, dyspnoea and exercise intolerance. Lifetime incidence in the 
Western world is high, at about one in four individuals20,21. Risk factors that predispose for 
atrial fibrillation are similar to those involved in other types of cardiovascular disease such as 
age, hypertension, diabetes and male gender. Overt cardiovascular conditions such as 
valvular disease and heart failure are also strong risk factors22. The issues with atrial 
fibrillation are several, with the most obvious one – from the patients’ perspective – being the 
symptoms caused by rapid and/or irregular pulse. These often appear unexpectedly and may 
be severe enough to prompt hospitalisation. Great efforts have been made to reduce 
symptoms related to atrial fibrillation, including a number of drugs developed in recent 
decades23. It is possible, however, that a rather new type of procedure called percutaneous 
ablation may emerge as the first line of treatment in patients with very pronounced 
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symptoms. The purpose of ablation therapy is to electrically isolate those segments of atrial 
tissue that most often initiate the arrhythmia, with the aim of permanently preventing new 
episodes24. Immediate symptoms aside, it has been increasingly recognised that atrial 
fibrillation is also associated with both increased mortality and morbidity in the longer term25. 
The risk of ischaemic stroke in particular is markedly elevated in many patients with atrial 
fibrillation. This is particularly true among the elderly26. In the late 1980s to the early 1990s, 
treatment with the oral anticoagulant warfarin was shown to drastically reduce this risk27. 
Over the last few years, a number of new drugs for stroke prevention have also emerged that 
may offer even further benefits compared to warfarin 28. 
 
 
1.3 THYROID HORMONES 
1.3.1 General effects 
Thyroid hormones, first isolated and described just over one century ago, affect most tissues 
in the human body29. Their main function is to regulate basal metabolic rate. The thyroid 
gland is regulated by the hypothalamic-pituitary axis through the influence of thyroid 
stimulating hormone (TSH), as part of a sensitive feedback system in which the pituitary 
gland adapts TSH production in response to circulating thyroid hormone levels. The major 
form of thyroid hormone produced is thyroxine (T4), which is converted to triiodothyronine 
(T3) peripherally. T3 is the biologically active form, but it has a shorter half-life than T4 and 
is therefore found in lesser quantities in the body30. 
 
1.3.2 Actions on the cardiovascular system 
Thyroid hormones have several different effects on the heart through both long-term 
transcriptional and short-acting non-genomic mechanisms. Myosin expression, intracellular 
calcium cycling and beta-adrenergic receptor expression represent a few of the intranuclear 
effects while direct changes to membrane ion transporters stand for some of the direct effects. 
 
 
 
 
 
 
Figure 2. Three-dimensional map of the left 
atrium of the heart obtained at the end of an 
atrial fibrillation ablation procedure.Image 
courtesy of Stockholm Arrhythmia Centre. 
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Peripheral vasculature is also affected through multiple signalling pathways, including 
membrane ion channels and endothelial nitric oxide synthase. Furthermore, the thyroid gland 
influences other organ systems in ways that indirectly affect hemodynamics, such as 
haematopoiesis in the bone marrow and renin production in the kidney. Tissue thermogenesis 
is also enhanced by thyroid hormones. In hyperthyroidism, this typically results in an 
increased heart rate, enhanced cardiac contractile function and diastolic relaxation, reduced 
peripheral vascular resistance, and an increased blood volume (illustrated in figure 3). All of 
these mechanisms act in combination to cause an increase in resting cardiac output of as 
much as 300% compared to euthyroid subjects. The subject has been most comprehensively 
reviewed by Klein et. al. in several reports31. 
 
Figure 3. Overview of the short-term effects of thyroid hormones on the cardiovascular system. The direct influence from 
triiodothyronine (T3) och cardiac chronotropy is the cause of palpitations experienced by many hyperthyroid patients. This, 
along with actions mediated through the kidneys and the vascular bed, may result in an three-fold increase of resting cardiac 
output. 
 
1.4 HYPERTHYROIDISM 
1.4.1 Prevalence, causes and treatments 
Most studies on the prevalence of hyperthyroidism have been conducted in developed 
countries. Estimates range from around 0.5%-2.0% in women, and about a tenth as much in 
men. Age influences these numbers, as does the level of iodine deficiency in the general 
population32. The most common causes of hyperthyroidism are Graves’ disease, toxic nodular 
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goitre, and toxic adenoma. Graves’ disease has an autoimmune aetiology, while the other two 
diagnoses (which share many common features and are henceforth referred to only as toxic 
nodular goitre) are caused by an autonomously overfunctioning thyroid gland. A recent 
survey from Sweden showed that the typical Graves’ disease patient is between 40 and 60 
years old while toxic nodular goitre has a peak incidence between 70 and 90 years of age33. 
Regardless of aetiology, hyperthyroidism can be cured through: 
1) Radioiodine treatment – Iodine is one of the main substrates of thyroid hormone and by 
administering radioactive iodine to patients, an accumulation of radiation to the thyroid gland 
is achieved, thus killing most or all of the tissue.  
2) Surgery, through which part (or the whole) of the thyroid gland is removed – In some 
cases both radioiodine and surgery are used in one and the same patient. 
3) Antithyroid drugs – These act by inhibition of thyroid hormone synthesis and are not 
curative per se, but they may give time to allow a transient hyperthyroidism to heal. 
Much research – including several randomised controlled trials34-38 – has been performed to 
compare efficacy and short-term complications between treatments, mostly in terms of 
relapse into hyperthyroidism and/or progression of ophthalmopathy. A recent meta-analysis 
concluded that in patients with Graves’ disease, radioiodine and surgery were equally 
effective in terms of relapse prevention, while antithyroid drugs were less effective39.   
However, only five previous studies have to our knowledge compared long-term adverse 
effects between different treatments for hyperthyroidism. The first one, performed in 1982, 
found no difference in mortality 
between 3,146 women treated with 
either radioiodine or surgery40. A few 
years later, other researchers found a 
slightly increased risk of 
cardiovascular death in 1,932 women 
treated with radioiodine compared to 
thyroidectomy or antithyroid drugs41. 
More recently  two studies focused on 
cancer incidence and cancer mortality 
in both men and women with regard to 
treatment modality but found no 
differences42,43. In 2013, one further 
study compared all-cause mortality 
between patients treated with either 
radioiodine or antithyroid drugs and 
found no clear differences44. No 
studies have explored all-cause and 
 
Figure 4. Forrest plot showing the relative risk (RR) of mortality 
in patients diagnosed with hyperthyroidism, stratified for 
treatment modality. 
Brandt et al, A critical review and meta-analysis of the 
association between overt hyperthyroidism and mortality, 
European journal of endocrinology / European Federation of 
Endocrine Societies 2011; 165(4): 491-7. Reprinted with 
permission by Bioscientifica Ltd. 
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cause specific mortality in both men and women; the only attempt at such an assesment was 
made in a meta-analysis by Brandt et al. in 2011, where pooled data from four cohort studies 
showed 17% higher all-cause mortality in hyperthyroid patients treated with radioiodine  
(figure 4). However, this finding did not reach statistical significance. 
 
1.4.2 Subclinical hyperthyroidism 
As thyroid hormone assays have improved and become more accessible over time, the 
concept of subclinical hyperthyroidism has attracted increasing attention. Because TSH 
production depends on a sensitive feedback loop, even slight changes of T3/T4 levels in an 
individual may cause large alterations in TSH levels. When TSH is suppressed below the 
reference range but T3 and T4 levels are normal, subclinical hyperthyroidism is considered to 
be present. The treatment guidelines of the American Thyroid Association state a subclinical 
hyperthyroidism prevalence of around 0.7%45. However, other researchers have suggested 
somewhat higher prevalences at roughly 2%. By and large, treatment options are the same as 
for overt hyperthyroidism. 
 
1.5 HYPERTHYROIDISM AS A RISK FACTOR 
1.5.1 General 
When the complications of hyperthyroidism are discussed, it must be remembered that this is 
a condition that follows a rather particular course over time. At the time of first diagnosis, the 
patient is in a so-called thyrotoxic state during which classic symptoms like palpitations, 
tremor, weight loss and nervousness may be present. After treatment the patient is generally 
rendered either euthyroid or hypothyroid on thyroxine substitution with few or no residual 
symptoms46. If hypothyroidism occurs, lifelong substitution with exogenous thyroxine is 
necessary. Most previous researchers have dealt with either ongoing or treated 
hyperthyroidism. These situations will, therefore, be addressed separately below. 
 
1.5.2 Cardiovascular conditions associated with ongoing thyrotoxicosis 
Arguably, the complication most commonly associated with hyperthyroidism is atrial 
fibrillation. Several researchers have confirmed an increased incidence of this arrhythmia in 
patients with thyrotoxicosis47,48. In the late 1970s and early 1980s, a number of studies were 
published that indicated an increased risk of thromboembolic events in thyrotoxicosis with 
AF49-51. There were, however, severe methodological weaknesses to these analyses with no 
possibility of discerning the thyroid disorder as an independent risk factor. In 1988, Petersen 
et. al. published results showing that when appropriate adjustments for baseline status were 
made, age was the only independent risk factor for stroke in thyrotoxicosis with concomitant 
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AF 52. The topic has been reviewed by Traube et. al. in 2011, who stated that current evidence 
might warrant the use of anticoagulation in this patient group unless contraindications to such 
treatment exist53. Support for this conclusion comes from another small but well-designed 
study by Siu et. al. from 2009 in which an increased risk of ischemic stroke was seen in 
subjects with thyrotoxicosis and AF compared to patients with AF alone, after adjustment for 
CHADS2- factors. 
The risk of heart failure has been mentioned above; the most comprehensive study to date 
was made by Siu et. al. (2007), who found clinical signs and symptoms of heart failure in 
5.8% of hyperthyroid patients admitted to a hospital clinic. However, only about half of these 
had impaired left ventricular function. After treatment of hyperthyroidism, persistent systolic 
heart failure remained in roughly 1% of the cohort54. 
 
1.5.3 Long-term complications after hyperthyroidism 
Several large register studies (here defined as those with more than 500 subjects included) 
have shown an increased risk of all-cause death in patients treated for hyperthyroidism41,55-60. 
(table 1). This observation was first made by Goldman et. al. in 1988 as part of the 
Thyrotoxicosis Follow-up Study in the U.S.A. The researchers’ primary aims were to assess 
mortality from all causes and cancer incidence, but specific causes of death were also 
reported. Comparisons were made to the general population. Within the cardiovascular 
spectrum, an increased risk of death due to atherosclerotic heart disease and rheumatic heart 
disease was found41. 
In 1993, Hall et. al. conducted a register study in Sweden to investigate the safety of 
radioiodine treatment that compared cases to the general population. The researchers found 
an increased risk of all-cause mortality with a standardised mortality ratio (SMR) of 1.47, 
largely due to cardiovascular and endocrine diseases55.  
Using a cohort of radioiodine treated subjects from the UK, Franklyn et. al. (1998) published 
their findings of increased all-cause mortality in subjects compared to the general population 
(SMR 1.13). The major underlying causes appeared to be cardiovascular and endocrine 
diseases61. The same research group refined their study method in another investigation from 
2005, in which it was demonstrated that this risk increase was no longer evident in patients 
rendered hypothyroid by treatment56. 
Two large register studies from Finland have approached this topic in a slightly different way, 
by using randomly selected sex- and age-matched control subjects from the general 
population for comparisons:  
Metso et. al. (2007) showed an increased all-cause mortality in 2,793 radioiodine treated 
subjects (HR 1.12) due to cardiovascular and endocrine diseases57. In 2008 these same 
researchers also demonstrated excess cardiovascular morbidity in the same cohort (HR 
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1.12)62. Ryödi et. al. (2013) could find no increased risk of death in 4,334 hyperthyroid 
patients treated with thyroid surgery; although the risk of cardiovascular morbidity was 
elevated (HR 1.15)63 
 
Table 1. Compilation of previous large ( > 1000 patients) studies on long-term effects of hyperthyroidism where at least one 
of the following outcomes were assessed: All-cause mortality, cardiovascular mortality, or cardiovascular morbidity. TNG = 
Toxic Nodular Goitre. RAI = Radioactive Iodine. CV = Cardiovascular. CVD = Cardiovascular disease. Dash signifies that 
no information exists. * not statistically significant, ** only specific cardiovascular diagnoses stated, † Graves' disease / TNG 
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Goldman 1988 1 762 1946-1978 17 _ no
Background 
population
1,3 1,4 _
Hall 1993 10 646 1950-1985 15 51/42 yes
Background 
population
1,47 1,65 _
Franklyn 1998 7 209 1950-1996 15 _ yes
Background 
population
1,13 1,2 _
Franklyn 2005 2 668 1984-2003 6 _ yes
Background 
population
1,14 1,19 _
Nyirenda 2005 2 230 1981-2001 _ 70/18 yes
Sex- and age 
matched
_ _ 1.42/1.5†
Flynn 2006 3 888 1994-2001 8 _ no
Background 
population
1.00* 0.89* 1.03*
Metso 2007 2 793 1965-2003 9 57/43 yes
Sex- and age 
matched
1,12 1,19 _
Metso 2008 2 611 1969-2003 9 60/40 yes
Sex- and age 
matched
_ _ 1,12
Ryödi 2013 4 334 1986-2009 _ 54/33 none
Sex- and age 
matched
_ 0.91* 1,15
Brandt 2013 3 006 1977-2008 6 _ _
Sex- and age 
matched
_ _ 1,34
Brandt 2013 2 152 1977-2008 11 60/40 _
Sex- and age 
matched
1,42/1,22† 1.49/0.94* _
Boelaert 2013 1 063 1989-2012 12 _ no
Background 
population and 
internal 
comparisons
1,15 1,2 _
Selmer 2014 3 902 2000-2009 6 _ _
Internal 
comparisons to 
euthyroid patients
1,25 _ 1,16
Laulund 2014 4 857 1995-2011 8 _ _
Internal 
comparisons to 
euthyroid patients
1,12 _ _
Dekkers 2017 85 856 1980-2012 9 _ no
Sex- and age 
matched
1,35 _ _**
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Two other studies from the UK likewise did not demonstrate any increased mortality in 
previously hyperthyroid subjects. Nyirenda et. al. (2005) examined 3,346 cases while the 
study by Flynn et. al. from 2006 was conducted on 3,888 patients of which only the 772 that 
were incident cases were analysed64,65. Nyirenda et. al. gathered a control group from patients 
hospitalised for reasons other than thyroid disease while Flynn et. al. used general population 
data for comparisons. However, Nyirenda et. al. demonstrated an increased risk of 
cardiovascular morbidity after treatment for both Graves’ disease (HR 1.42) and toxic 
nodular goitre (HR 1.50), while Flynn et. al. found an increased risk only for AF specifically 
(HR 2.7). 
During the last few years, results from several large register studies have been reported by 
Danish researchers. In most of these, patients have been included not on the basis of 
treatment for hyperthyroidism but through collection of abnormal thyroid values gathered 
from laboratory databases. In 2013, Brandt et. al. found increased hazard ratios for all-cause 
death of 1.42 and 1.22 in patients with Graves’ disease and toxic nodular goitre, 
respectively58. However, only patients from the Graves’ disease group had any demonstrable 
increase in cardiovascular causes of death. Controls were age- and sex-matched individuals 
from the general population58. In a study from 2014, Selmer et. al. could reveal an increased 
all-cause mortality (HR 1.25) largely due to cardiovascular disease, using euthyroid 
individuals as controls59. Furthermore, Laulund et. al. (2014) reported increased mortality 
(HR 1.12) in a similar cohort, using euthyroid individuals as controls60. The most recent 
Danish study – and the largest one of its kind to date – was published by Dekkers et. al. in 
2017, showing increased all-cause mortality (HR 1.35) as well as increased cardiovascular 
morbidity after hyperthyroidism66. 
Two large studies from Taiwan have examined a few specific cardiovascular diagnoses only; 
Sheu et. al. (2010) observed an increased risk for cerebrovascular morbidity while Lin et. al. 
(2010) reported an increased risk of pulmonary embolism67,68. 
Overall, an association between hyperthyroidism and cardiovascular disorders seems to exist. 
However, it is unclear whether this applies to all types of hyperthyroidism, and whether 
modern cardiovascular care have affected outcomes. The causal links behond the connection 
are also largely unknown.  
Cardiovascular disease spans a range of specific diagnoses that deserve further mentioning: 
In thyrotoxicosis, the only cardiovascular disease that seemed to be definitely more prevalent 
was AF. As for treated hyperthyroidism, although only some of the above studies reported 
outcomes in detail, cerebrovascular disease was most frequently stated as a specific cause of 
death or hospitalisation (5 studies57,61,62,66,67) followed by arrhythmias (4 studies62,63,65,66), 
heart failure (2 studies62,63), and valvular disease (2 studies57,61). Ischaemic heart disease or 
pulmonary embolism were specifically mentioned in two studies respectively61,66,68, and 
disorders of the pulmonary circulation in only one61. 
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In a pooled meta-analysis on studies from before 2011, Brandt et. al. concluded that the risks 
of all-cause and cardiovascular mortality were both increased, with relative risks of 1.21 and 
1.13 respectively, in patients treated for hyperthyroidism (figure 5)69. 
 
 
 
1.5.4 Complications from subclinical hyperthyroidism 
The association between subclinical hyperthyroidism and cardiovascular disease has attracted 
considerable attention in the last few decades. AF in particular has been the main point of 
interest. In a publication from 1979, Forfar et. al. presented data suggesting that subclinical 
hyperthyroidism – which was at the time defined by the response to an assay named TRH-test 
– might be a common cause of lone AF70. In a subsequent study, the same authors claimed 
that AF in such cases might be possible to treat with antithyroid drugs71. This finding was 
contested by Giladi et. al. in 1991 who found no increased prevalence of subclinical 
hyperthyroidism in a group of 25 subjects with lone AF72 and who also pointed to 
methodological weaknesses in previous studies. 
However, in a seminal paper from 1994 on subjects from the Framingham Cohort, Sawin et. 
al. demonstrated a 10-year cumulative AF incidence of 28% in persons with very suppressed 
TSH-levels, yielding a relative risk of 3.1 compared to euthyroid subjects even after 
adjustment for known risk factors for AF73. A similar observation was made by Auer et. al. in 
Figure 5. Forrest plots showing the 
relative risk (RR) of mortality in 
patients diagnosed with 
hyperthyroidism. All studies (panel 
A), and mortality due to 
cardiovascular disease (panel D). 
Brandt et al, A critical review and 
meta-analysis of the association 
between overt hyperthyroidism and 
mortality, European journal of 
endocrinology / European 
Federation of Endocrine Societies 
2011; 165(4): 491-7. Reprinted with 
permission by Bioscientifica Ltd. 
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2001 who in a large cross-sectional study at a hospital clinic found a relative risk for AF of 
2.8 in patients with subclinical hyperthyroidism after adjustment for AF risk factors74. 
Cappola et. al. (2006) likewise found an increased relative AF risk of 1.9 after adjustments 
over a 12-year follow-up period among elderly participants in the Cardiovascular Health 
Study75. The reason for this lower number might have been due to counting of incident AF 
only, something which was not done in earlier studies. The risks of death from all causes, 
ischaemic heart disease or cerebrovascular disease were not increased. 
In 2007, Gammage et. al. reported an odds ratio of 1.89 for AF in subjects with subclinical 
hyperthyroidism, using cross-sectional data from a primary care setting76. Data from the 
Rotterdam Study, a population based cohort of elderly people, also showed an increased 
relative risk of AF of 1.97 when the quartile with the lowest TSH values was compared to the 
quartile with the highest values77. Using pooled individual participant data from 10 cohorts 
Collet et. al. demonstrated increased risks of death from all causes (HR 1.24), death from 
ischaemic heart disease (HR 1.29), morbidity due to ischaemic heart disease (HR 1.21) and 
AF (HR 1.68). No increased risk of stroke was seen78.  
To conclude, subclinical hyperthyroidism may to some degree affect the risk of AF, overall 
cardiovascular disease and possibly even mortality, but the association is not entirely clear. 
This thyroid disorder is possible to cure using the same methods as for overt hyperthyroidism, 
something which has led to debate regarding possible indications for treatment. However 
controlled intervention studies are lacking. At present, guidelines from the American Thyroid 
Association strongly recommend treatment in patients with very suppressed TSH levels who 
are older than 65 years, postmenopausal women, individuals with cardiovascular risk factors 
or those with symptoms of hyperthyroidism. If TSH levels are only moderately suppressed, 
treatment “should be considered” using the same criteria, with an exception made for 
menopausal women.45 
During the last few years, it has been debated whether free T4 levels close to the upper level 
of the normal range might also represent a clinically relevant form of excessive thyroid 
function, even in the absence of suppressed TSH levels. Researchers have shown that within 
groups of patients treated with atrial fibrillation ablation, individuals with the highest free T4 
concentrations appear to relapse more frequently into AF79,80. A very recent meta-analysis by 
Baumgartner et al. (2017) actually concluded that free T4 levels, but not TSH levels, 
correlated to incident atrial fibrillation (figure 6, courtesy of  Wolters Kluwer Health Inc)81. 
Also very recently, a study from the Rotterdam cohort showed that higher T4 levels were 
associated with coronary calcification, incident cardiovascular disease, and cardiovascular 
death; a similar negative correlation, albeit much weaker, was found for TSH82. 
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Figure 6. Association between quartiles of free thyroxine within the reference range and the risk of atrial fibrillation. 
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2 AIMS 
The general purpose of this project was to study the relation between hyperthyroidism and 
cardiovascular disease. The specific aims and hypotheses of each study were as follows: 
 
Study I: To analyse the association between hyperthyroidism and cardiovascular mortality 
and morbidity in the long term. Our hypothesis was that hyperthyroidism increases the risk of 
all-cause and cardiovascular death; this has been suggested from previous research by others 
but rarely in any cohort as large as the one available to us. Further aims were to investigate 
the impact of different causes of hyperthyroidism, and to examine changes over time.  
 
Study II: To investigate the long-term impact of treatment with radioiodine vs surgey for 
hyperthyroidism in terms of both mortality and morbidity. Our hypothesis was that the choice 
of treatment significantly affects these outcomes. 
 
Study III: To assess the prevalence of subclinical hyperthyroidism in patients admitted for 
ablation of AF. Our hypothesis was that AF patients would be more likely to suffer from 
subclinical hyperthyroidism than individuals without AF. 
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3 MATERIAL AND METHODS 
 
In short, Papers I and II were both register studies largely based on the same group of 
patients: Stockholm residents treated for hyperthyroidism between the years 1976-2000. 
Paper III was a cross-sectional study that consecutively enrolled patients and controls from 
two arrhythmia ablation clinics in Stockholm between the years 2013-2015. For practical 
reasons, the word “thyroidectomy” – which usually implies complete resection of the thyroid 
gland – will henceforth be used as a catch-all term to describe all types of thyroid gland 
surgery, including partial resections. 
 
3.1 PATIENTS 
3.1.1 The Swedish national registers 
Sweden has a very long history of population registration dating back to the 17th century83. 
Consequently, national authorities have had access to reliable data on the vital and migration 
status of each citizen for centuries. In 1947 personal identity numbers – unique 10-digit 
identifiers – became mandatory for all citizens and other permanent residents. This facilitated 
the development of various national healthcare registers, most of which were maintained by 
the Board of Health and Welfare. In 1952, construction began on the causes of death register 
which came into full effect in 1961. The patient register, which deals with hospital contacts, 
was first launched in 1964 and reached full coverage with regard to inpatient care (all 
diagnoses and all regions of the country) in 1987. From the year 2000, polyclinical hospital 
contacts were also added to this data base. Furthermore, a register on dispensed drugs was 
started in 200584. Digitalisation had already begun in 1967, and large volumes of data have 
also been transferred to electronic records retrospectively. Aggregated data are posted online 
for the general public while individual-level data are made available to researchers upon 
approval by an ethics review board. The personal identity numbers enable cross-matching 
between healthcare registers which may then be matched again to census data. This makes 
possible the creation of very large healthcare cohorts that stretch back decades in time with 
little loss to follow-up85-87. 
In the present studies (numbers I and II), individuals who had undergone thyroidectomy were 
extracted from these national registers. That group was then merged with, or compared to, the 
group from the Stockholm Radioiodine Cohort (SIC, see below). Since the latter consisted 
solely of Stockholm residents treated between the years 1976-2000, similar exclusion criteria 
were applied to the thyroidectomy group so that only Stockholmers treated during that same 
period were included. This was done in order to avoid any potential bias due to geography or 
temporal variations. 
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3.1.2 The Stockholm Iodine Cohort 
Radioiodine treatment has been used as a means of treating hyperthyroidism since the 
1940s88. Since its discovery, the method rapidly became widespread and was implemented in 
most developed countries, including at various centres in Sweden. However, because 
treatment with radioiodine is usually performed in a polyclinical setting, no information about 
these treatments exists in the national patient register. Medical records from Sweden’s 
nuclear medicine clinics have therefore been compiled by different researchers into a data 
base that has been updated on several occasions; at present, it consists of patients treated or 
examined with different radioactive substances (radioactive iodine or technetium) between 
the years 1950-2000. This material is commonly referred to as the Swedish Radioiodine 
Cohort, and it has previously been used in several research projects55,89-91. 
A subset of the Swedish Radioiodine Cohort is the Stockholm Radioiodine Cohort (SIC), a 
data base compiled from the hospital records of Radiumhemmet at Karolinska University 
Hospital (which has always been the sole provider of nuclear isotope therapy in the greater 
Stockholm area). The part of the SIC that covers the years 1976-2000 is considered to be the 
only portion that is essentially complete. For this reason, a choice was made to use only the 
SIC (as opposed to the entire Swedish Iodine Cohort) for the present studies and only for that 
time period. It contains detailed information on investigations and treatments where 
radioactive isotopes are used. For hyperthyroid patients, the probable etiology of 
hyperthyroidism is stated in over ninety per cent of cases as well as details about the 
treatment (doses of radioiodine, number of treatments etc.). Because radioiodine treatment is 
a form of outpatient care, it was not registered in national health data bases prior to the year 
2000. 
 
3.1.3 Electrophysiology centres in Stockholm 
The greater Stockholm area comprises two units dedicated to invasive electrophysiological 
studies and catheter ablations. The first and largest of these is located at Karolinska 
University Hospital (Karolinska sjukhuset or KS), which is publically funded and treats 
mainly patients from the Stockholm region and adjacent regions. This centre treats patients 
with AF as well as other conditions, such as AV-nodal re-entry tachycardias (AVNRT:s) and 
ventricular arrhythmias. The second unit is the Stockholm Arrhythmia Centre (SAC), which 
is partly funded by private insurances and almost exclusively treats AF. The SAC receives 
patients from the whole of Sweden. Taken together, the two centres performed almost 800 
AF ablations during 2016. 
 
3.2 STUDY I 
The national patient register and the SIC were used to collect data on all Stockholm residents 
treated for hyperthyroidism with either radioiodine or thyroidectomy between 1976-2000 
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(data on patients treated with anti-thyroid drugs were not obtained due to the fact that such 
information was not compiled in national registers during this time period). These were 
defined as an exposed population (i.e. exposed to hyperthyroidism). To obtain a reference 
group, data was also collected from the patient register on individuals that had been treated 
with surgery for non-toxic goitre. Because these patients had no hyperthyroidism, they were 
defined as an unexposed population (figure 7). 
 
 
Figure 7 Flowchart describing how the study cohort was assembled. 
 
The index date for all study patients was defined as the first date of treatment (with 
radioiodine or thyroid surgery). Only patients who had an index event between 1976-2000 
were included, but diagnoses recorded in the patient register from between 1969-1975 were 
also taken into account as markers of baseline comorbidity. Patients younger than 18 or older 
than 90 years at the time of their index event were also excluded.  
Subjects were followed until death, emigration or end of study (31 December, 2012). When 
all-cause mortality was analysed, census data from Statistics Sweden were used up until 11 
December, 2013. Information about cause-specific mortality was gathered from the Swedish 
causes of death register. When these outcomes were assessed, only the underlying cause was 
taken into account for each deceased subject. 
All individuals (both radioiodine treated and surgically treated) were then matched to the 
entire patient register for the period 1969-2000 in order to find other diagnoses related to any 
earlier hospitalisations that would constitute relevant baseline comorbidity. The main 
diagnosis and up to five secondary diagnoses were taken into account for each hospital 
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contact. For internal analyses within the cohort, adjustment was made for prevalent diabetes, 
hypertension, renal failure, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary 
disease. For each outcome, adjustment was also made for whether that particular diagnosis 
was already present at baseline.  
Diagnostic codes were categorized according to ICD8-ICD10, and a translation was made 
between the different classifications. 
 
3.2.1 Statistical analyses 
Mortality and morbidity outcomes were both assessed in two ways: exposed (hyperthyroid) 
subjects versus the general population and exposed subjects versus unexposed (nontoxic 
goitre) subjects. 
In order to estimate the risk of death for exposed versus unexposed subjects, a Cox 
proportional hazard regression was fitted, adjusting for sex, age of inclusion (using restricted 
cubic spline), and year of inclusion (using restricted cubic spline). In order to assess potential 
differences in cause specific hazard ratios, a cause specific proportional hazards model was 
used, treating other deaths as censored92. Because mean age was known to vary considerably 
according to type of hyperthyroidism, outcomes were also stratified into quartiles according 
to age at index event.  
The Patient Register was used to identify incident cardiovascular morbidity after inclusion, 
using the same procedure as for baseline comorbidity but with follow-up until 2012. Because 
death is a competing event, the notion of cause-specific hazard regression was used, treating 
death as censored. To assess the change in hazard ratio over time for all cardiovascular 
disease, a flexible parametric model was used93. Stratification according to age was done in 
the same manner as for mortality. Further stratification according to time of the index event 
was performed by assessing incident morbidity separately for patients included before or after 
the year 1990. 
Comparisons were also made to the general population of Stockholm regarding both 
morbidity and mortality. All three etiologies of thyroid disorders – Graves’ disease, toxic 
nodular goitre, or nontoxic goitre –  were analysed separately. When mortality was assessed, 
Standardized Mortality Ratios (SMR) for death due to both all-cause mortality and any 
cardiovascular disease were used. The expected number of deaths was calculated by 
multiplying the mortality rates in the background Stockholm population (divided into strata 
of 5-year age groups, sex and for each of the years between 1976 and 2013) by the stratum-
specific person-time in the cohort. Cause specific SMR was calculated between 1998-2012. 
When morbidity was assessed, standardised incidence rate ratios for the group of 
cardiovascular diseases as a whole were used. Standardisation was done for sex and age, and 
results were presented for each of the years between 1998 and 2012.  
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Adjustment for levothyroxine use as a variable that affected outcomes was not possible due to 
the fact that the last index event took place in the year 2000 while the first entry in the drug 
register was made in 2005. However, prescription data from 2005 were used to assess 
hypothyroidism in those study patients that were still alive at that time. 
All analyses were performed in Stata 13.1 software (Stata Corp, College Station, TX 77845, 
USA).  
 
3.3 STUDY II 
Essentially the same cohort as in Study I was used in Study II. Thyroidectomised individuals 
were collected from the patient register, and radioiodine treated individuals were gathered 
from the SIC. However, a few further exclusion criteria were applied: First, patients with 
nontoxic goitre were not part of the analysis. Second, patients younger than 35 years at the 
index event were excluded because females (who make up the large majority of hyperthyroid 
patients) below that age are rarely recommended radioiodine as treatment for 
hyperthyroidism. The third and last group excluded was of those patients in whom the 
aetiology of hyperthyroidism was uncertain or those who had received both radioiodine and 
surgical treatment in order to reduce the risk of confounding. Outcomes were assessed in 
terms of all-cause and cause-specific mortality (figure 8). 
 
 
Figure 8 Description of assembly of the study cohort. 
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3.3.1 Statistical analyses 
We applied three different statistical methods: regression adjustment, propensity score 
matching, and inverse probability weighting94. In the regression analyses, we used a Cox 
regression model that adjusted for all the potential confounders to estimate HRs and 95% 
Confidence Intervals (95% CIs). In the propensity score matching and inverse probability 
weighting analyses, we calculated propensity scores estimating the probability of receiving 
surgical treatment using a logistic regression model. For propensity score match analysis, a 
one-to-one nearest-neighbour matching algorithm without replacement was employed in 
order to pair each subject receiving surgical treatment with one subject receiving radioiodine 
treatment. Propensity score matching allows the estimation of the average treatment effect 
among the treated. This permits one to make inferences about the effects of surgical treatment 
in those patients that actually underwent surgery. In the inverse probability weighting 
analyses, we applied standardised mortality ratio weights95. In short, this means that surgery 
patients are given a weight of 1, while radioiodine patients are given a weight equal to the 
ratio of the estimated propensity score to one minus the propensity score. We chose to use 
standardised mortality ratio weights as their use results in an estimate of the average 
treatment effect among the treated, which is the same quantity estimated in the 
aforementioned propensity score analysis . After matching or weighting, we checked again 
for balance in the confounders using standardised differences. Finally, for both propensity 
score match and inverse probability weighting analyses, Cox regression models including 
treatment as the only covariate were used. To account for the matched nature of the sample 
(propensity score matching) or for the probability weights, we used a robust estimator of the 
variance-covariance matrix94. 
 
3.4 STUDY III 
Study subjects were patients admitted at KS and SAC for catheter ablation of AF. Control 
subjects were patients admitted to those same clinics for catheter ablation of AVNRT. All 
individuals deemed eligible for inclusion were required to give written informed consent 
before participation. The exclusion criteria were as follows: AF patients who had not tried at 
least one anti-arrhythmic medication prior to ablation, subjects who had undergone ablation 
before, and subjects with a known thyroid disorder of any kind. Information about co-
morbidity and continuous medication was collected using a clinical research form upon 
inclusion or, in some cases, retrospectively from medical records (figure 9). Blood samples 
for assessment of thyroid hormone levels (TSH, T3, and free T4) were drawn less than 7 days 
before the ablation procedure. Subclinical hyperthyroidism was defined as a TSH level below 
0.3 mIU/L with T3 and free T4 levels within the reference range.  
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Figure 9. Inclusion and analysis of study subjects from two electrophysiology clinics in Stockholm, Sweden. 
 
3.4.1 Statistical analyses 
Given the uncertainty concerning the prevalence of subclinical hyperthyroidism in the general 
population and in particular among patients admitted for catheter ablation, an adaptive design 
was chosen. Assuming a prevalence of 7% in the AF group and of 1.4% in the control group, 
our power calculation showed that 412 patients would need to be included for a power of 
80% and a 5% two-sided level of significance. An interim analysis was planned after 
inclusion of at least 50 patients in each group, using the Hwang-Shih-DeCani spending 
function and assuming that the trial stop for futility. Student’s t-test was used for comparison 
of continuous variables, while the χ2 or Fisher’s exact test were used to compare nominal 
variables. Adjustments of thyroid hormone levels were made using linear regression analysis 
for the following baseline variables: sex, age, body mass index, and amiodarone use. 
 
3.5 ETHICAL CONSIDERATIONS 
Studies I and II were approved by the Ethics Review Board of Stockholm, reference number 
2013/638-31/3. Because this research was register based, a few particular ethical 
considerations had to be made. The most obvious drawback was that it was impossible – even 
in theory – to obtain individual consent from the tens of thousands of patients involved; a 
significant number of these had already died when our cohorts were compiled. Furthermore, 
the national data bases were never meant to be reserved strictly for research purposes; 
authorities also use them for administrative reasons and for statistics. In the Swedish 
healthcare system, patients are virtually never given the possibility to opt out of this kind of 
registration. Because research is clearly involved, one might ask whether this practice is fully 
in compliance with the Declaration of Helsinki. Another ethical issue is Sweden’s use of 
personal identity numbers which, however practical they may be, introduce the risk of 
careless cross-linkage between registers. The resulting data sets may contain more (sensitive) 
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information about individual persons than what was originally intended. Sweden’s national 
authorities address this problem by de-identifying all data before it is handed over to 
researchers, which was also the case in the present studies in which none of the authors had 
access to personal identity numbers. In addition, permission from an ethics review board is 
mandatory before data may be extracted.  
Study III was approved by the Ethics Review Board of Stockholm, reference number 
2012/1437-31/1. In this investigation the study subjects were recruited prospectively, and 
their written consent was required. Each patient was given information prior to enrolment. 
The study was purely observational and thus did not expose participants to any risk from 
potentially hazardous or ineffective treatments. An adaptive study design was used so that 
recruitment could be stopped before the inclusion goal was reached if the data suggested so.  
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4 RESULTS 
4.1 STUDY I 
4.1.1 Exposed versus unexposed patients 
The selection procedure resulted in a study cohort consisting of 15,924 individuals. Among 
these were 12,239 patients treated for hyperthyroidism (exposed) and 3,685 patients treated 
for nontoxic goitre (unexposed). Within the hyperthyroid group there were 6,284 cases with 
Graves’ disease and 5,702 with toxic nodular goitre; a further 289 cases had no defined 
aetiology of hyperthyroidism. The proportion of women was 84.7% with sex ratios roughly 
equivalent between groups (p = 0.46). Median ages differed considerably between patients 
with Graves’ disease (54.4 years), toxic nodular goitre (68.6 years) and nontoxic goitre (49.1 
years) (table 2). 
  
 
Table 2. Demographic characteristics, treatment modalities and baseline comorbidities of the participants treated with 
radioiodine or thyroidectomy between 1976-2000 in Stockholm, Sweden. *Percentages  in relation to whole group with this 
thyroid disorder. Totals may not sum to 100 due to rounding. ** Also included in the overall category of cardiovascular 
diseases. ***Any previous malignancy diagnosis, not specified as  ongoing or cured. † p values for comparisons between all 
hyperthyroid patients and nontoxic goiter group. 
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Number of subjects (total = 15,924) 12,239 6,248 5,702 289 3,685
Women, % 84.8 82.6 87.3 86.5 84.3 0.46 †
Mean age, years 61.3 54.4 68.6 34.9 49.1 < 0.001
Age quartiles, n  (%)*
1st quartile (18-45 years) 2,411 (19.6) 1,753 (28.1) 423 (7.4) 235 (81.3) 1,439 (39.1)
2nd quartile (46-58 years) 2,899 (23.6) 1,870 (29.9) 987 (17.3) 42 (14.5) 1,212 (32.9)
3rd quartile (59-70 years) 3,096 (25,3) 1,395 (22.3) 1,692 (29.7) 9 (3.1) 747 (20.3)
4th quartile (71-90 years) 3833 (31,3) 1,230 (19.7) 2,600 (45.6) 3 (1.0) 287 (7.8)
Treatment, n  (%)*
Radioiodine 10,346 (84.5) 5,090 (81.5) 5,256 (92.2) 0 0
Thyroidectomy 1,694 (13.8) 1,047 (16.8) 382 (6.7) 265 (91.7) 3,647 (99.0) < 0.001
Both treatments 199 (1.6) 111 (1.8) 64 (1.1) 24 (8.3) 38 (1.0)
Baseline comorbidities, n  (%)*
Cardiovascular disease 3,175 (25.9) 1,261 (20.2) 1,902 (33.4) 12 (4.2) 381 (10.3) p < 0.001 
Hypertension** 527 (4.3) 166 (2.7) 360 (6.3) 1 (0.3) 72 (2.0) p < 0.001 
Ischemic heart dis** 815 (6.7) 295 (4.7) 520 (9.1) 0 73 (2.0) p < 0.001 
Atrial fibril lation** 1,118 (9.1) 396 (6.3) 719 (12.6) 3 (1.0) 39 (1.1) p < 0.001 
Heart failure** 877 (7.2) 294 (4.7) 583 (10.2) 0 22 (0.6) p < 0.001
Ischemic stroke** 266 (2.2) 81 (1.3) 184 (3.2) 1 (0.3) 9 (0.2) p < 0.001
Renal failure 118 (1.0) 53 (0.8) 62 (1.1) 3 (1.0) 14 (0.4) p = 0.001
COPD 216 (1.8) 75 (1.2) 140 (2.5) 1 (0.3) 25 (0.7) p < 0.001
Rheumatoid arthritis 131 (1.1) 55 (0.9) 76 (1.3) 0 15 (0.4) p < 0.001
Psoriasis 26 (0.2) 12 (0.2) 14 (0.2) 0 7 (0.2) p = 0.793
Diabetes 471 (3.9) 168 (2.7) 302 (5.3) 1 (0.3) 60 (1.6) p < 0.001
Cancer*** 729 (6.0) 288 (4.6) 437 (7.7) 4 (1.4) 119 (3.2) p < 0.001
< 0.001
Exposed
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Mean follow-up time was 18.5 years, ranging from one day to 37.9 years. Total time at risk 
was 295,246 person-years. Among the 9,650 patients still alive by the year 2005, 93% were 
prescribed levothyroxine in the Graves’ disease group, 57% in the toxic nodular goitre group, 
and 63% in the nontoxic goitre group. 
When all incident cardiovascular morbidity (as opposed to mortality) was assessed for the 
combined hyperthyroid group compared to the nontoxic goitre group, hazard ratios were 
found to be highest just after inclusion but remained elevated for a long time thereafter 
(figure 10). 
 
 
For both Graves’ disease patients and toxic nodular goitre patients, atrial fibrillation was the 
diagnosis with the highest incidence at one year of follow-up with HR:s of 4.62 (CI 2.25-
9.51) and 5.35 (CI 2.61-10.97), respectively. During the mean follow-up time of 18.5 years, 
increases in risk among Graves’ disease patients lost statistical significance while toxic 
nodular goiter patients remained at increased risk (figure 11). 
For the whole follow-up period, all-cause mortality was increased (HR 1.27,  (CI 1.20-1.35) 
as was cardiovascular mortality (HR 1.29,  (CI 1.17-1.42) for the hyperthyroid group 
compared to the nontoxic goitre group. Separate analyses according to aetiology of 
hyperthyroidism yielded an increased risk of all-cause mortality both for Graves’ disease (HR  
1.14, CI 1.03-1.27) and for toxic nodular goitre (HR 1.42, CI 1.28-1.57). Significant 
differences were also found for the shorter follow-up time of 10 years (figure 12). The risk of 
death from cardiovascular disease was likewise significantly increased regardless of aetiology 
of hyperthyroidism or length of follow-up.  
Figure 10. Hazard ratios for all 
cardiovascular morbidity over time during 
whole follow-up (mean 18,5 years); All 
hyperthyroid patients compared to reference 
group of nontoxic goiter patients. Shaded 
area represents the 95% confidence interval. 
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Figure 11. Forest graphs depicting hazard ratios for different types of incident cardiovascular disease in hyperthyroid 
(Graves’ disease (GD) or toxic nodular goitre (TNG)) patients at two separate time points during follow-up. The reference 
group (dashed vertical line) consisted of patients treated for nontoxic goitre. Adjusted for sex, age, prevalent diabetes, 
hypertension, renal failure, rheumatoid arthritis, psoriasis, and chronic obstructive pulmonary disease. Each incident 
diagnosis was also adjusted for its own baseline prevalence. 
 
 
Figure 12. Comparisons of all-cause and cardiovascular mortality for different lengths of follow-up; Horizontal bars denote 
hazard ratios and 95% confidence intervals for Graves’ disease (GD) and toxic nodular goiter (TNG). Dashed vertical line 
denotes the reference group of nontoxic goiter patients. Adjustments for baseline factors were made as for figure 11. 
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When the cohort was divided according to time of inclusion (before and after the year 1990), 
all-cause and cardiovascular mortality were increased in both types of hyperthyroidism for 
both time intervals. Cardiovascular morbidity was likewise increased among toxic nodular 
goitre patients included both before and after year 1990. For the Graves’ disease patients, 
morbidity was higher only among those included after year 1990 (figure 13).  
 
 
Figure 13. Comparisons of all-cause and cardiovascular mortality, as well as cardiovascular morbidity, stratified according 
to inclusion time before or after 1990; Horizontal lines represent Graves’ disease (GD) and toxic nodular goiter (TNG) with 
95% confidence intervals compared to nontoxic goiter (vertical dashed lines). Adjusted for sex, age, prevalent diabetes, 
hypertension, renal failure, rheumatoid arthritis, psoriasis, and chronic obstructive pulmonary disease. Each incident 
diagnosis was also adjusted for its own baseline prevalence. 
 
4.1.2 Exposed and unexposed patients versus general population 
In comparison to the general population, all-cause mortality was increased among 
hyperthyroid subjects with a standardised mortality ratio (SMR) of 1.22 (CI 1.20-1.25). The 
same was true for cardiovascular mortality (SMR 1.26,  (CI 1.20-1.32). Both the Graves’ 
disease group and the toxic nodular goitre group displayed increased all-cause and 
cardiovascular mortality by themselves. Nontoxic goitre patients showed no excess mortality 
compared to the general population (table 3). 
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Table 3. Comparisons of mortality; Graves’ disease, toxic nodular goitre and nontoxic goitre versus general population of 
Stockholm for 1998-2012. Adjusted for sex and 5-year age groups. * During the period of 1976 – 2013. ** During the period 
of 1998 – 2012. 
 
Cardiovascular morbidity as compared between the cohort and the general population are 
displayed as year-by-year standardised incidence-rate ratios in figure 14. 
 
 
 
SMR 95% CI SMR 95% CI SMR 95% CI SMR 95% CI
Death from all causes* 1.22 1.20 - 1.25 1.07 1.05 - 1.15 1.35 1.31 - 1.39 0.95 0.90 - 1.00
Cardiovascular death** 1.26 1.20 - 1.32 1.12 1.04 - 1.20 1.38 1.30 - 1.47 0.96 0.86 - 1.06
Nontoxic GoiterAll Hyperthyroidism Graves' Disease Toxic Nodular Goiter
Figure 14. Comparisons of 
cardiovascular morbidity; Graves’ 
disease, toxic nodular goiter and 
nontoxic goiter versus general 
population during the years 1998-
2012. Vertical lines denote 
standardized incidence ratios with 
95% confidence intervals for each 
of these diagnoses year by year. 
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Point estimates were higher than 1.0 for each of the three groups in all of the years, but these 
increases were not always statistically significant. The toxic nodular goitre group differed 
most clearly from the general population, showing significantly increased cardiovascular 
morbidity in 14 out of the 15 years observed. 
 
4.2 STUDY II 
After further exclusion criteria were applied to the cohort described in Study I, 10,992  
 Radioiodine Surgery p value* d # 
  (n = 10250) (n = 742)   
     
Age at treatment (years)     
35-45 915 (8.9) 394 (53.1)  1.086 
45-55 1925 (18.8) 191 (25.7)  0.168 
55-65 2270 (22.1) 101 (13.6) <0.001 -0.224 
65-75 2752 (26.9) 43 (5.8)  -0.594 
75-90 2388 (23.3) 13 (1.8)  -0.688 
Mean 64.0 47.0  -1.461 
     
Women 8668 (84.8) 633 (85.3) 0.688 0.015 
     
Year of treatment     
1976-1979 1557 (15.2) 136 (18.3)  0.084 
1980-1984 1995 (19.5) 144 (19.4)  -0.001 
1985-1989 2188 (21.4) 141 (19.0) <0.001 -0.058 
1990-1994 2295 (22.4) 123 (16.6)  -0.147 
1995-2000 2215 (21.6) 198 (26.7)  0.119 
     
Type of hyperthyroidism     
Graves' disease 5004 (48.8) 465 (62.7)  
<0.001 
 
Toxic nodular goiter 5246 (51.2) 277 (37.3) -0.281 
     
Comorbidities at baseline     
Ischemic heart disease 812 (7.9) 3 (0.4) <0.001 -0.383 
Myocardial infarction 261 (2,6) 2 (0,3) <0.001 -0.194 
Atrial fibrillation 1090 (10.6) 20 (2.7) <0.001 -0.322 
Cerebrovascular disease 538 (5,3) 6 (0,8) <0.001 -0.261 
Stroke 260 (2.5) 5 (0.7) 0.001 -0.148 
Heart failure 864 (8.4) 10 (1.4) <0.001 -0.333 
Cardiomyopathy 18 (0,2) 1 (0,1) 0.796 -0.01 
COPD 208 (2.0) 5 (0.7) 0.010 -0.117 
Renal failure 103 (1.0) 4 (0.5) 0.212 -0.053 
TAO 867 (8.5) 98 (13.2) <0.001 0.153 
Hypertension 509 (5.0) 15 (2.0) <0.001 -0.161 
Diabetes 453 (4.4) 7 (0.9) <0.001 -0.216 
Cancer 693 (6.8) 25 (3.4) <0.001 -0.155 
 
Table 4. Baseline characteristics of 10992 Stockholm residents treated for hyperthyroidism between 1976-2000. Treatment 
modalities were radioiodine and surgery.  Percentages are stated within brackets and calculated separately for each 
treatment group. COPD, chronic obstructive pulmonary disease; TAO, thyroid associated ophthalmopathy. *p values from 
chi-squared test. d# standardized difference. 
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individuals remained. Of these, 10,250 had received radioiodine treatment, and 742 had 
received surgical treatment for hyperthyroidism. The radioiodine group had a median age of 
65.1 years and the thyroidectomy group of 44.1 years, and the sex ratios were 84.8% and 
85.3% women respectively. Levels of baseline comorbidity were substantially higher among 
radioiodine treated subjects (table 4). 
In the regression analysis, there were 7,007 deaths during whole follow-up, with a total 
number of person-years at risk of 179,409 equivalent to a mean follow-up time of 16.3 years. 
The propensity score match included 1,484 individuals of which 400 died; total observation 
time was 33,074 person years, and mean follow-up time was 22.3 years. In the inverse 
probability weighting, 1,476 subjects were included, 386 of which died. Total observation 
time was 32,911 years and mean follow-up 22.3 years (table 5). 
 
  Regression analysis Propensity score matching Inverse probability weighting 
(n = 10992) (n = 1484) (n = 1478) 
Nr of 
deaths 
Hazard ratio Nr of 
deaths 
Hazard ratio Nr of 
deaths 
Hazard ratio 
All-cause* 7007 0.82 (0.71-0.96) 400 0.80 (0.68-0.94) 387 0.85 (0.72-1.00)** 
Cancer 1378 1.04 (0.80-1.36) 122 1.05 (0.75-1.48) 121 1.07 (0.82-1.41) 
Cardiovascular 
disease 
3324 0.70 (0.53-0.91) 143 0.64 (0.48-0.86) 132 0.74 (0.56-0.97) 
Other causes 2126 0.78 (0.59-1.04) 120 0.74 (0.53-1.05) 117 0.78 (0.58-1.04) 
 
Table 5. Comparisons of  mortality in hyperthyroid patients treated with surgery versus radioiodine,  during a period of 
follow-up between 1976-2013. Three different statistical methods were used. Mean follow-up time was 16,3 years when 
regression analysis was applied; in the propensity score match and the inverse probability weighting, mean follow-up time 
was 22,3 years. Numbers within brackets denote 95% confidence intervals. * Number of all-cause deaths exceeds the sum of 
deaths from specific causes, since no data on causes of death was available for the year 2013. ** p = 0.044 for this 
observation. 
 
Surgically treated subjects had lower all-cause mortality as assessed by cox regression (HR 
0.82, CI 0.71-0.96), propensity score matching (HR 0.80, CI 0.68-0.94), and inverse 
probability weighting (0.85, CI 0.72-1.00, p = 0.044) compared to subjects who received 
radioiodine. (table 5 and figures 15 and 16). Significantly lower cardiovascular mortality was 
also found among thyroidectomised individuals in all three analyses; the HR by cox 
regression was 0.70 (CI 0.53-0.91), by propensity score matching 0.64 (CI 0.48-0.86), and by 
inverse probability weighting 0.74 (CI 0.56-0.97).  No clear differences were found regarding 
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cancer mortality or other causes of death. One further unexpected finding was made in the 
regression analyses which showed that men in particular had a markedly lower risk of dying 
if treated with surgery as opposed to radioiodine (HR 0.45, CI 0.30-0.67). 
 
 
Figure 15. Kaplan-Meier survival curves describing all-cause mortality in patients treated for hyperthyroidism with 
radioiodine versus surgery, according to the propensity score match analysis. 
 
 
Figure 16. Kaplan-Meier survival curves describing all-cause mortality in patients treated for hyperthyroidism with 
radioiodine versus surgery, according to the inverse probability weighting analysis. 
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4.3 STUDY III 
Three hundred twelve participants were recruited. Among these, 212 had a diagnosis of AF 
(cases), and 100 had an AVNRT diagnosis (controls). The AF group had a mean age of 59.4 
years and consisted of 77.8% men. The AVNRT group had a mean age of 51.1 years and 
consisted of 40.0% men. Mean body mass index, age, and sex ratios differed significantly 
between groups (table 6).  
 
Table 6. Patient characteristics according to arrhythmia. BMI= Body mass index; TIA = Transient ischemic attack; TSH= 
Thyroid stimulating hormone. FT4 = Free thyroxine; FT3 = Free triiodothyronine. *Amiodarone: ongoing treatment, or 
discontinued less than 3 months ago. 
 
One (1) patient with subclinical hyperthyroidism was found in the AF group, while none 
were found in the AVNRT group. As a consequence further inclusion into the study was  
 
Figure 17. Box plot showing the observed TSH levels in the two study groups. 
 32 
stopped for futility. When thyroid hormone concentrations were compared between cases and 
controls as continuous variables, no statistically significant differences in mean levels of TSH 
(figure 17) or T3 could be found. However, levels of free T4 differed significantly between 
groups, with a mean concentration that was 0.8 pmol/L higher among AF patients (95% CI 
for difference 0.31-1-35, p = 0.002) (figure 18). 
 
Figure 18. Box plot showing the observed FT4 levels in the two study groups. 
 
After adjustments for sex, age, BMI, and amiodarone using multivariate linear regression, a 
significant difference in mean FT4 remained (95% CI, 0.03-1.23, p = 0.039) (figure 19). No 
significant differences in mean TSH or FT3 levels were observed after adjustments.   
 
Figure 19. Box plot showing FT4 levels adjusted for age, sex, BMI and amiodarone in the two study groups. All the extremes 
in the AF plot are patients with amiodarone treatment. 
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AF patients on recent or ongoing amiodarone treatment (n=13) had higher mean FT4 
concentrations (18.7 pmol/L) but lower mean FT3 concentrations (4.23 pmol/L) compared to 
16.6 pmol/L and 4.69 pmol/L respectively in AF patients not on amiodarone (95% 
confidence interval of difference, 0.92 – 3.35, p = 0.001 for FT4; and -0.78 – -0.14, p = 0.006 
for FT3). Patients on amiodarone treatment constitute the extremes illustrated in the AF box 
plot as seen in figure 19. 
When patients with amiodarone treatment were excluded, AF patients still had significantly 
higher mean FT4 levels compared to the control group; both before (mean difference 0.7 
pmol/L, 95% CI, 0.18 – 1.21, p = 0.008) and after adjustments for sex, age, and BMI (95% 
CI, 0.02 – 0.71, p = 0.038) (figure 20).  
 
Figure 20. Box plot, with amiodarone treated patients excluded, showing predicted FT4 values adjusted for sex, age, and 
BMI in the two study groups. 
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5 DISCUSSION 
The main conclusion from our first two studies is that patients treated for hyperthyroidism are 
at increased risk of hospitalisation and death in the long term. Individuals with toxic nodular 
goiter represent the group with the largest risk, and this finding has not changed over time. 
However, surgically treated patients - especially men – seem to fare better in the long term. In 
our third study, we did not find an increased prevalence of subclinical hyperthyroidism 
among AF ablation patients, although this group had significantly higher levels of free T4. 
 
5.1 STUDY I 
We found an increased risk of all-cause death as well as cardiovascular disease and death 
among patients treated for hyperthyroidism. The risk of all-cause mortality for the whole 
hyperthyroid group was elevated by 27%, a number that lies remarkably close to the 21% risk 
increase found in an earlier meta-analysis that was based on similar patients but older data69. 
One particular paper deserves further mentioning here because it has had a marked impact on 
the way that long-term risk is viewed on this topic: In 2005, a British research group showed 
that radioiodine treated subjects had increased all-cause and cardiovascular mortality 
(compared to the general population) only if they were still hyperthyroid or euthyroid after 
treatment56. In other words, iatrogenic hypothyroidism should perhaps be regarded as the 
preferred outcome. This conclusion is intuitively appealing to most physicians, and we 
attempted to address it in our study; however, since hypothyroidism is virtually never a cause 
for hospitalisation, it was not possible to use patient register data to this end. Instead we 
searched the drug register to find levothyroxine users among those patients still alive in 2005. 
We could thus demonstrate very high prevalences of hypothyroidism among all patients, both 
those treated for hyperthyroidism and for nontoxic goitre. This finding seems to contradict 
the earlier notion that hypothyroidism as such is beneficial, seeing as how the nontoxic group 
did not have a lower risk than the general population. However, we wish to emphasize that 
such a conclusion is only valid if one accepts the assumption that post-treatment 
hypothyroidism was roughly as prevalent among patients that died before 2005. 
Stratification according to calendar year of inclusion did not indicate a lower risk in patients 
who were treated for hyperthyroidism after year 1990 than in those treated earlier, compared 
to nontoxic goitre patients. There were also no apparent differences over time when 
comparisons were made to the general population. Several previous studies have analysed the 
impact of different time periods as a continuous variable, but none of these have found the 
calendar year of inclusion to significantly affect outcomes.41,42,44,55,59. To our knowledge only 
one other study has divided patients into strata depending on year of inclusion. In 2014, 
Finnish researchers reported that among patients who had undergone surgery for 
hyperthyroidism between 1986-2007, those operated after 1996 had a 20% higher risk of 
cardiovascular hospitalization compared to those treated earlier.63 Our study yielded similar 
results but also demonstrated higher ratios of all-cause and cardiovascular mortality over 
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time. Taken together we believe these findings signal a worrying trend that requires further 
investigation in the future. 
When outcomes in terms of cardiovascular hospitalization were examined at different lengths 
of follow-up, a striking rise in the incidence of AF – considerably higher than for any other 
diagnosis - was observed one year after inclusion. This was likely an effect of the well-known 
correlation between hyperthyroidism and AF47. It was only through a much longer period of 
follow-up that clear increases in other cardiovascular diagnoses could be found. An 
interesting thought is whether residual AF from hyperthyroidism might lead to other types of 
cardiovascular morbidity over time.  
We found that the highest cardiovascular risk was confined to toxic nodular goitre patients as 
opposed to patients with Graves’ disease. There is no obvious explanation for this. The 
results from those previous register studies that have compared aetiologies have been 
conflicting 58,62-64. It is possible that the duration of hyperthyroidism plays a role here. 
Graves’ disease often has a rapid onset with explicit symptoms. By contrast, toxic nodular 
goitre can linger as subclinical hyperthyroidism for several years before it progresses to 
thyrotoxicosis96. It is possible that such prolonged exposure to high levels of thyroid hormone 
has lasting detrimental effects on the heart and vessels. 
Although the overall connection between hyperthyroidism and cardiovascular disease has 
been demonstrated before by other research groups, many previous studies have only used the 
background population for reference, thereby excluding the possibility of adjusting for any 
comorbidities. In the light of decreasing cardiovascular mortality in the developed world 
during the last decades, the relevance of some of the earliest findings on this subject could 
also be brought into question. We have explored the association between hyperthyroidism 
and cardiovascular disease in particular. This was done both by using a very large cohort and 
by comparing our study subjects to different reference populations, using recently updated 
registers to assess outcomes.  
 
5.2 STUDY II 
In this study, our main finding was that thyroidectomy as treatment for hyperthyroidism was 
associated with a lower long-term risk of dying compared to radioiodine. The difference in 
cardiovascular mortality between groups was the main reason for this finding. Males in 
particular seemed to benefit most from surgical treatment. In general, our results did not vary 
significantly across the different statistical methods used. 
To the best of our knowledge, these findings have not been described before; on the other 
hand, the topic does not seem to have ever been comprehensively studied, at least not in 
males and/or for other outcomes than cancer. As a rule, it is always difficult to separate any 
inherent effects of a disease from the side-effects of its treatment if randomised trials are 
lacking. Given the known association between hyperthyroidism and cardiovascular risk, any 
 36 
conclusions about treatment effects become particularly treacherous. However, a recent study 
from Denmark found an elevated risk of cerebrovascular disease in both hyperthyroid and 
nontoxic goitre patients who were treated with radioiodine, something which might imply a 
negative effect from radioiodine as such97. This cannot explain the difference between men 
and women found in our study; however, it is possible that radioiodine represents a 
cardiovascular risk factor that has a greater impact in a male population, considering that the 
cardiovascular risk profile among men in general is higher. Another explanation might be 
found from a study which showed that men are less likely than women to become 
hypothyroid from treatment with radioiodine98. Although we were not able to investigate this 
possibility in our cohort, it can be hypothesised that mean time to remission was longer 
among males treated with radioiodine than among those who received surgery. As discussed 
in study I, this might increase cardiovascular risk in the long run.  
 
5.3 STUDY III 
Here, we found no increased prevalence of subclinical hyperthyroidism among patients 
admitted for AF ablation (cases) compared to those admitted for AVNRT ablation (controls). 
In fact, the overall prevalence of subclinical hyperthyroidism was rather low compared to the 
general population prevalence stated in the literature99. Our finding is at odds with a previous 
retrospective study performed by our research group in which we found subclinical 
hyperthyroidism in 10% of AF ablation patients when medical records were scrutinised 
retrospectively. This discrepancy might possibly be because amiodarone use has decreased 
over the last few years. Amiodarone is a potent agent for treating arrhythmias, but it is well 
known to increase the risk of thyroid dysfunction due to its very high iodine content. 
This project was based on the hypothesis that subclinical hyperthyroidism might be a 
contributing factor behind some of the most therapy-refractory cases of AF. Because catheter 
ablation can be seen as the last line of treatment, the prevalence of subclinical 
hyperthyroidism should be particularly high among AF patients referred for this procedure. 
Both overt and subclinical hyperthyroidism are associated with an increased risk of AF.74-
76,100 In patients with hyperthyroidism-induced AF, only about 60% spontaneously convert to 
sinus rhythm if euthyroidism is restored101,102. Among the remaining 40%, however, the 
arrhythmia persists. This might be explained by the promotion of substrates for AF in the 
heart by a process of remodeling (sometimes referred to as “AF begets AF”).103 Thus, early 
detection and treatment of subclinical hyperthyroidism in individuals with AF may perhaps 
have an impact on the recurrence of AF after catheter ablation. 
Although our primary hypothesis was not verified in this study, we found a mean level of free 
T4 that was significantly higher among AF patients, even after adjustments were made for 
baseline differences between groups. High normal FT4 levels have previously been 
associated with an increased prevalence76 and incidence of AF 77.  It has also been suggested 
to predict recurrence of AF after catheter ablation79,80.  
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5.4 STRENGTHS AND LIMITATIONS 
Analyses in Studies I and II were largely based on information collected from healthcare 
registers. This method of research is almost invariably connected with both unquestionable 
strengths and clear limitations. The most obvious strengths of both these projects are the size 
of the cohort and the very long follow-up time. Another strength comes from the structure of 
the Swedish healthcare registers which enable cross-matching between data bases; along with 
the system of personal identity numbers and census data, few patients are ever lost to follow-
up. In Study I we collected thousands of nontoxic goitre patients for use as a reference group 
to our hyperthyroid cases. We argued that these subjects were more suitable for comparison 
than the general population or randomly selected controls because they had also received 
treatment for a thyroid disorder. Furthermore, results from internal comparisons 
(hyperthyroidism versus nontoxic goiter) were cross-checked with population level data. 
Potential confounding due to age differences between groups was addressed both by 
adjusting for age as a continuous variable, and by stratifying for age upon inclusion.  
Limitations of these register studies include a lack of complete information on important 
parameters such as body weight, smoking, and several comorbidities; hypertension, for 
instance, has a much higher “true” prevalence than can be found from healthcare registers. 
Also, even though the Swedish patient register is considered to be reliable with regards to 
several cardiovascular diagnoses, the death register has not been as conclusively validated.  
Another limitation is the fact that diagnostic methods, treatment guidelines, and definitions of 
disease have changed considerably over the last decades. For instance, ICD codes and codes 
for surgical procedures have been re-defined twice since the beginning of our inclusion 
period in 1976. Furthermore, important diagnostic methods such as assays for thyroid 
receptor antibodies and cardiac troponin markers were not widely available forty years ago. 
Another example is the gradual realisation among endocrinologists during the ‘80s and ‘90s 
that the choice of treatment for Graves’ disease might affect the progression of 
ophthalmopathy. Taken together, all of these changes are likely to have affected both 
treatments and diagnostics in ways that we were unable to adjust for. 
Furthermore, we did not have access to information about possible subclinical dysfunction 
prior to inclusion into the study, and we did not know how patients responded to treatment 
(although we did know that the proportion of levothyroxine treated individuals was high in 
each group in 2005). Also, patients treated with antithyroid drugs were not included because 
they were not registered in national databases during the time period studied. It should also be 
noted that there was no one in the unexposed group of nontoxic goitre patients that had 
received radioiodine treatment. Lastly, radioiodine treated patients were gathered from a 
different data base than were surgically treated patients. It is possible that this might have 
skewed our assessment of baseline co-morbidity. 
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A few further considerations apply to study II: The use of three different statistical methods 
lends increased reliability to the final results, since these were by and large consistent with 
each other. Co-variables were well balanced, with all absolute standardized differences lower 
than 0.1. However, no amount of statistical adjustment could ever circumvent the possibility 
of indication bias when different treatments are compared to each other in a non-randomised, 
non-blinded fashion. 
Study III is, to the best of our knowledge, the first of its kind to use a control group to 
investigate the prevalence of subclinical hyperthyroidism among catheter ablation patients. 
Other strengths include the use of clinical research forms to assess baseline co-variates, and 
systematic prospective collection of data. The difference in gender distribution and mean age 
between groups constitute study limitations. Furthermore, it is plausible that the low 
prevalence of subclinical hyperthyroidism was affected by patients not being referred to 
catheter ablation due to subclinical thyroid dysfunction.  
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6 CONCLUSIONS 
In summary, the following conclusions can be drawn: 
• Although hyperthyroidism is considered curable, it is nevertheless a diagnosis 
associated with an increased risk of death and cardiovascular disease in the long term. 
• AF is the cardiovascular diagnosis with the highest incidence in the short term after 
hyperthyroidism of any aetiology. In the longer term, patients with toxic nodular 
goitre appear to have a particularly unfavourable risk profile in general. Future 
research might clarify whether the increased incidence of other diagnoses – most 
notably stroke – is due to residual AF.  
• Advances in cardiovascular care during the last decades do not seem to have 
diminished the risk. 
• Surgery as treatment for hyperthyroidism is associated with a lower risk of all-cause 
and cardiovascular death compared to radioiodine treatment. 
• Previously undiagnosed subclinical hyperthyroidism, defined as a suppressed TSH 
level, is not a common finding among AF patients referred for catheter ablation. 
• The mean level of T4 is higher among AF patients than among controls. Future 
studies should investigate whether this finding has implications for relapse into AF 
after ablation. 
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7 CLINICAL IMPLICATIONS & FUTURE PERSPECTIVES 
Risk stratification is key as regards primary prevention of cardiovascular disease. It is 
possible that a history of hyperthyroidism should be considered yet another risk factor, along 
with such conditions as hypertension or smoking. In that case, increased vigilance for 
cardiovascular disease might be beneficial for this group. One concrete example of this could 
be AF screening, a procedure that has attracted increasing attention during recent years104. As 
shown in Study I, AF incidence is increased at an early stage after hyperthyroidism, and one 
might speculate whether the increased findings of other cardiovascular diagnoses later on 
might be a sign of inadequate medication with anticoagulants and substances for rate control. 
It should also be remembered that paroxysmal AF without symptoms – so-called “silent” AF 
– is known to be quite common in the general population; whether this is also the case among 
formerly hyperthyroid patients is not known105. To explore this question, the author is 
currently conducting an AF screening study in patients undergoing treatment for 
hyperthyroidism.  
As for other cardiovascular risk factors, it is of course impossible to retrospectively change 
the fact that a patient was once hyperthyroid. However, other actions may be taken in order to 
reduce his or her total risk. Examples include the use of lipid lowering or antihypertensive 
drugs or programmes for smoking cessation. There is also one public policy measure that 
may reduce the incidence of hyperthyroidism worldwide: Programmes that aim to increase 
the level of iodine intake in areas of iodine deficiency should, in the long run, lead to a lower 
incidence of hyperthyroidism (especially toxic nodular goitre). 
In a wider perspective, it is worth noting that hyperthyroidism is not the only metabolic 
hormone disturbance associated with diseases of the hearts and vessels. The most notorious 
among the other endocrine disorders is of course diabetes, the cardiovascular consequences of 
which have been quite thoroughly studied. However, less is known about the reasons for the 
increased cardiovascular risk that seems to be connected with, for instance, Cushing’s disease 
or hypertestosteronism106-108. Although theories on this topic abound for thyroid disorders as 
well as for each of these other conditions, further research might be warranted to look for any 
possible common denominators between them. 
Regarding our findings on differences between treatments for hyperthyroidism, one might 
consider surgery to be recommended as first-line treatment. However, register studies are not 
the firmest of foundations upon which to construct treatment recommendations. It is a 
disturbing fact that large randomised controlled trials are missing in this field. Such studies 
are warranted in order to change practice guidelines. For now, however, the best way forward 
will most likely be to conduct further research on other registers or healthcare cohorts. 
Fortunately, many medical centres worldwide that treat hyperthyroidism – in particular those 
that deal with radioiodine – already have a tradition of long-term follow-up. Although this is 
mainly done for the purpose of finding patients with late-onset hypothyroidism, the data 
might also be used to estimate the incidence of cardiovascular disease in the long term. It 
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should not be impossible to include persons treated with surgery or antithyroid drugs in these 
cohorts. 
As for our third study, we have found no evidence that intensified screening for subclinical 
hyperthyroidism in AF ablation patients would be useful. We did, however, find an elevated 
mean level of free T4 among individuals with AF. Although this was an unexpected finding 
and not the answer to our initial hypothesis, it seems to be in accordance with other studies. 
As intriguing as this observation may be, the truly important issue here is whether T4 levels 
affect ablation success rates. At present the aim of any new similar investigation would be to 
confirm a correlation between thyroid hormones and AF ablation outcomes. Should this be 
the case, interventional trials that use randomized allocation of treatments to lower hormone 
levels would likely be a logical next step. The percentages of patients with atrial flutter or 
AVNRT who experience recurrences post-ablation are presently down to single digits. One of 
the ultimate goals within electrophysiology is to reach similar results for AF patients. 
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8 SVENSK SAMMANFATTNING 
Hjärtkärlsjukdom är fortfarande den ledande dödsorsaken i västvärlden, även om risken 
minskat under senare årtionden till följd av förbättrade levnadsvanor och nya möjligheter till 
diagnostik och behandling. En av hjärtkärlforskningens viktigare uppgifter är den så kallade 
kardiovaskulära preventionen; med detta menas att man försöker utröna vilka faktorer som 
statistiskt sett hänger samman med en ökad sannolikhet för insjuknande i allvarliga 
sjukdomar som exempelvis hjärtinfarkt och stroke. Den informationen kan bland annat 
användas för att urskilja individer som löper ökad risk att drabbas, och därigenom finns 
möjlighet att rikta utredningar och förebyggande åtgärder mot dessa – samt att undvika 
överbehandling av andra. Även om många så kallade riskfaktorer redan är kända – rökning 
och högt blodtryck är ett par välkända exempel – så finns det fortsatt ett behov av att försöka 
finna ytterligare bitar i det pussel som utgör kardiovaskulära risk. 
Hypertyreos (i dagligt tal ofta kallat giftstruma) är en sedan länge känd åkomma som uppstår 
då sköldkörteln – som i vanliga fall styr kroppens ämnesomsättning – blir överaktiv och 
börjar producera för stora mängder sköldkörtelhormon. Den klassas som en botbar 
folksjukdom som drabbar cirka två procent av alla svenskar någon gång i livet, företrädesvis 
kvinnor. Inte sällan uppstår uttalade och typiska symtom som leder den kliniska utredningen 
rätt i tidigt skede. Diagnos ställs enkelt genom blodprovtagning, ofta via primärvården. Det 
händer dock att både laboratoriemässiga förändringar och symtom är mer diskreta; man talar 
då om subklinisk hypertyreos, ett tillstånd som blivit föremål för allt mer forskning på senare 
år. Tidigare studier talar för att personer som insjuknar i hypertyreos (av antingen den vanliga 
eller subkliniska sorten) löper ökad risk att dö i förtid trots att hormonrubbningen behandlats 
framgångsrikt. Detta tycks åtminstone delvis bero på en ökad risk för hjärtkärlsjukdom hos 
denna grupp på lång sikt. Slutsatserna baseras dock till viss del på äldre studier, från en tid då 
både utrednings- och behandlingsmöjligheterna vid hjärtkärlsjukdom var betydligt mindre 
utvecklade. Vad gäller de andra, nyare studierna så byggde ett flertal sina resultat på 
jämförelsegrupper som möjligen inte var de mest relevanta i sammanhanget. 
Vårt syfte med detta projekt var att vidare undersöka kopplingen mellan sköldkörtelsjukdom 
och hjärtkärlsjukdom med hjälp av uppdaterade data och delvis nya metoder. De två första 
arbetena är så kallade registerstudier baserade på data från de svenska befolknings- och 
sjukvårdsregistren, som tillsammans med sina motsvarigheter i norden är unika vad gäller 
långtidsuppföljning och tillförlitlighet. Det tredje delarbetet är en klinisk studie där vi 
undersökt sambandet mellan svårbehandlat förmaksflimmer och subklinisk hypertyreos. 
Metod och resultat 
I delarbete I inhämtade vi information om patienter som genomgått tyreoidektomi 
(fullständigt eller partiellt avlägsnande av sköldkörteln medelst kirurgi) från det nationella 
patientregistret. Information om patienter som behandlats med radioaktivt jod inhämtades 
från en databas baserad på journaluppgifter. Data över kardiovaskulära utfall och död 
samlades från patientregistret, det nationella dödsorsaksregistret, samt Statistiska 
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centralbyrån. Det svenska läkemedelsregistret användes också för att utvärdera 
levaxinmedicinering. Studiepersonerna utgjordes av i princip samtliga invånare i Stockholms 
län som genomgått antingen tyreoidektomi eller radiojodbehandling under perioden 1976-
2000. Kohorten följdes fram till år 2012. De som behandlats för hypertyreos betraktades som 
exponerade individer, medan de som behandlats för icke-toxisk struma definierades som en 
icke-exponerad kontrollgrupp. Jämförelser gjordes även mot Stockholms 
bakgrundsbefolkning. Resultaten visade en ökad risk för död oavsett orsak, samt ökad risk för 
både kardiovaskulär sjukdom och död, hos hypertyreosgruppen (12 239 individer) jämfört 
med gruppen med icke-toxisk struma (3 685 individer). Liknande skillnader sågs även vid 
jämförelser mot normalbefolkningen. Risken var större för patienter med toxisk knölstruma 
än för patienter med Graves’ sjukdom (två vanliga orsaker till hypertyreos). Vi fann ingen 
antydan till minskad risk hos patienter som inkluderades efter 1990, jämför med dem som 
inkluderats tidigare. 
Delarbete II baserades i huvudsak på hypertyreosgruppen från delarbete I. Vi använde tre 
olika statistiska metoder för att utröna om valet av behandling vid hypertyreos  (kirurgi eller 
radiojod) har någon betydelse för framtida risk för död och sjukdom. 10 250 patienter som 
behandlats med radiojod jämfördes med 742 patienter som behandlats med tyreoidektomi. 
Resultaten visade en minskad risk för död oavsett orsak, samt för kardiovaskulär död, hos 
patienter som behandlats med kirurgi. Detta gällde oavsett analysmetod. Särskilt män verkade 
dra fördel av kirurgi. 
Delarbete III var en så kallad tvärsnitsstudie, i vilken vi mätte halterna av 
sköldkörtelhormoner hos patienter som var på väg att genomgå ablationsbehandling av 
förmaksflimmer (ett kateterburet ingrepp i hjärtat som brukar reserveras för särskilt 
svårbehandlade rytmrubbningar). Vår hypotes var att just denna grupp borde ha en hög 
förekomst av subklinisk hypertyreos, vilket också var något vi sett vid en journalgenomgång 
som föregick detta arbete. Som jämförelsegrupp använde vi oss av patienter som genomgick 
ablationsbehandling av andra rytmrubbningar än förmaksflimmer. Våra resultat visade dock 
ingen statistiskt signifikant skillnad i förekomst av subklinisk hypertyreos; däremot så fann vi 
signifikant högre nivåer av fria sköldkörtelhormoner hos förmaksflimmerpatienterna.  
Slutsatser 
• Hypertyreos är en sjukdom som sammanhänger med ökad risk för kardiovaskulär 
sjukdom och död på lång sikt. 
• Toxisk knölstruma är associerad med högre risk än Graves’ sjukdom. 
• I valet mellan radiojod och kirurgi som behandling av hypertyreos är den senare 
metoden att föredra, då den är förenad med lägre risk för kardiovaskulärt insjuknande 
och död på lång sikt. 
• Patienter som remitteras för ablation av förmaksflimmer har inte någon ökad 
förekomst av subklinisk hypertyreos. 
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